Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-PEAK: REGN7508 and REGN9933 for VTE Prophylaxis in PICC Patients
NCT07697599Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 3 trial of REGN7508, amrecibart in venous thromboembolism (VTE), sponsored by Regeneron Pharmaceuticals. Started Sep 2026; status: recruiting.
02
Drugs
REGN7508amrecibart
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07697599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697599.